Jacqueline Miles
Primary Care · Grand Prairie, TXNPI 1073143327
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Merz North America, Inc. accounts for 69.0% of it on its own, with 19 other manufacturers making up the rest. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $61.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$6K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$196
- Novo Nordisk$170
- Galderma Laboratories, L.p.$142
- Lilly USA, LLC$133
- plus $696 from 14 others
What the payments were for
- Consulting fees$1,20014%
- Travel & lodging$2,52030%
- Food & beverage$4,80556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 53 | $5,880 |
| Biohaven Pharmaceuticals, Inc. | 8 | $1,307 |
| AbbVie(2 entities) | 9 | $196 |
| Novo Nordisk | 11 | $170 |
| Galderma Laboratories, L.p. | 1 | $142 |
| Lilly USA, LLC | 14 | $133 |
| Boehringer Ingelheim | 8 | $120 |
| AstraZeneca | 6 | $95 |
| Adlon Therapeutics L.p. | 3 | $63 |
| Amarin Pharma, Inc. | 3 | $62 |
| Amgen | 3 | $62 |
| Merck | 4 | $59 |
| Johnson & Johnson | 4 | $53 |
| Upsher-smith Laboratories LLC | 3 | $50 |
| Pfizer | 2 | $39 |
| Eisai Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $12 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$4,329
- NURTEC ODT$1,200
How this compares
$8,525 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 11 | $434 |
| Ondansetron OdtOndansetron | 39 | $358 |
| Amlodipine Besylate | 11 | $3 |
Paid to pharmacies, not to this prescriber.
Other primary care in Grand Prairie
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
- Hannah LancasterMcKinney$9K
- Christopher LoganSan Antonio$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.